AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for CD70 antigen

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for protein-protein interfaces.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P32970

UPID:

CD70_HUMAN

Alternative names:

CD27 ligand; Tumor necrosis factor ligand superfamily member 7

Alternative UPACC:

P32970; B4DPR8; Q53XX4; Q96J57

Background:

The CD70 antigen, also known as CD27 ligand or Tumor necrosis factor ligand superfamily member 7, plays a pivotal role in the immune system. It is a cytokine that binds to CD27, crucial for T cell immunity, especially during antiviral responses. This interaction promotes T-cell proliferation and the development of cytolytic T-cells.

Therapeutic significance:

CD70's involvement in Lymphoproliferative syndrome 3, an immunologic disorder leading to increased susceptibility to Epstein-Barr virus and B-cell malignancies, highlights its therapeutic potential. Targeting the CD70-CD27 pathway could offer new strategies for treating this syndrome and related B-cell disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.